Phase 3 Trial of BudesonideFormoterol Inhaler Versus Standard Asthma Care in South African Children and Adolescents Aged 6 to 18 Years
Led by University of KwaZulu · Updated on 2026-01-15
1038
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the effectiveness of budesonideformoterol inhalers compared to the standard asthma treatments in reducing asthma flare-ups over one year in children and adolescents aged 6 to 18 years with mild to moderate asthma. The study focuses on participants who have had at least one asthma exacerbation in the past year and is conducted as a Phase 3 randomized controlled trial at a single center. The trial addresses the high burden of asthma in South African children and adolescents and seeks to provide evidence for improved, affordable treatment approaches in low- and middle-income countries.
Participants are randomly assigned to one of two groups one group receives budesonideformoterol inhalers at doses adjusted by age and symptom severity, used both for symptom relief and maintenance the other group continues with the standard care involving separate inhalers for relief and maintenance, prescribed by their doctors. The budesonideformoterol is delivered via inhalers with doses of 804.5 for children aged 6-11 and 1604.5 for those 12-18 years, taken as needed or twice daily depending on control. The study lasts 52 weeks, with visits at 13, 26, 39, and 52 weeks, including telephone follow-ups to monitor asthma attacks and medication changes.
Throughout the study, participants undergo lung function tests, including peak flow measurements and bronchodilator reversibility testing, to confirm asthma diagnosis and monitor control. Researchers collect data on asthma exacerbations, hospital or clinic admissions, adverse events, and medication adjustments. Safety and trial conduct are overseen by independent expert committees. The main outcome is the number of asthma exacerbations over 52 weeks, with cost-effectiveness also evaluated. Participants and their families are supported and followed for the full year duration of the trial.
CONDITIONS
Brief Title
Anti-Inflammatory Reliever South Africa
Research Team
R
Refiloe Masekela, PhD
N
Nompumelelo Ngobese
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
At least one asthma exacerbation in the past year requiring systemic corticosteroids or hospitalization
Written consent from participant or guardian and assent where applicable
Willingness to comply with study procedures and attend visits including telephone contacts
You will not qualify if you...
Active tuberculosis or contact with active TB cases within the last 6 months
Chronic sputum production, chest pain, shortness of breath, dizziness, or light-headedness in last 2 months
Cardiac arrhythmia
Chronic conditions such as thyrotoxicosis, phaeochromocytoma, cardiovascular disease, severe hypertension
Uncontrolled diabetes mellitus
Peak expiratory flow rate less than 50% predicted (severe asthma)
History of life-threatening asthma episodes requiring intubation or associated with severe complications
Use of biological or immunomodulatory therapy for asthma (e.g., methotrexate, regular oral prednisolone)
Any condition affecting drug absorption or participant safety as judged by investigator
Physical, mental, or social conditions, or lab abnormalities that may interfere with study participation
Inability to attend follow-up or plans to leave study area within 12 months of enrollment
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 52 weeks
Participants receive budesonide/formoterol or standard of care asthma therapy to manage their asthma symptoms.
Regular visits during treatment period as per study protocol
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Phase 4 Multicenter Study on Starting Airsupra in the Emergency Department to Improve Asthma Outcomes Compared to Usual Care
Study of Inflammatory Lung Diseases Including Asthma, COPD, Bronchiectasis, Cystic Fibrosis, PCD, and ILD to Understand Patient Characteristics and Improve Personalized Treatment
Phase 1 Randomized Study Comparing Pharmacokinetics of Two GSK5784283 Formulations in Healthy Adults by Injection
Evaluating Different Lung Function Tests Including Impulse Oscillometry for Diagnosing Asthma in Adults
Evaluating Two Doses of Glycopyrronium Inhaler Compared to Placebo with Budesonide and Formoterol in Children 4 to Under 12 Years with Asthma
Randomized Feasibility Study of Nocturnal CPAP Compared to Standard Care in Adults with Large Airway Collapse
Study to Assess Patient Characteristics and Outcomes in Asthma Across Different Severities in Real-World Care
A Cross-Sectional and Prospective Observational Study of Asthma Disease Burden and Control
Phase 3 Open-label Study to Assess Depemokimab as Add-on Treatment for Asthma with Type 2 Inflammation in Children Aged 6 to 11 Years
Evaluating Depemokimab as an Add-On Treatment for Adolescents and Adults with Type 2 Asthma at Risk of Exacerbations Compared to Placebo and Standard Care
Evaluating HB0056 Injection for Adults with Moderate to Severe Asthma
Randomized, Double-Blind, Placebo-Controlled Study of Safety and Effectiveness
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Anti-inflammatory reliever therapy for asthma using inhaled budesonide/formoterol as-needed with or without maintenance in South African children (AIR-SA 001): a description of a randomised clinical trial protocol.